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Vpr is one of the auxiliary proteins of HIV-1 and is selectively incorporated into the virion by a process involving the C-
terminal p6 portion of the Gag precursor Pr55. Vpr and the matrix protein p17 are the components of the viral preintegration
complex and appear to play important roles in the nuclear transport of proviral DNA in nondividing cells. In the present
study, we have demonstrated by coimmunoprecipitation experiments that Vpr associates with matrix protein p17 but not
with capsid protein p24 within the HIV-1 virion. Experiments employing the yeast two-hybrid GAL4 assay for protein–protein
interactions also demonstrated a direct association between Vpr and the C-terminal region of matrix protein p17. Association
of Vpr and the matrix protein p17 within the mature virion is consistent with their collaborative role in the nuclear transporta-
tion of the viral preintegration complex in nondividing cells such as macrophages. q 1996 Academic Press, Inc.
Human immunodeficiency virus types 1 and 2 (HIV-1 Vpr exists in association with MA p17 within the mature
HIV-1 virion.and HIV-2) are the etiological agents of the acquired
Wild-type NL432 strain HIV-1 (WT) and its Vpr-negativeimmunodeficiency syndrome (AIDS) (1). In addition to the
mutant (EN) were produced by transfection of a humanstandard retroviral proteins, Gag, Pol, and Env, HIVs en-
colon carcinoma cell line SW480 with pNL432 infectiouscode six auxiliary proteins: Tat, Rev, Nef, Vif, Vpr, Vpu
clones (23). EN produces a highly unstable Vpr due to(only in HIV-1), and Vpx (only in HIV-2) (2). Among them,
truncation of the C-terminal 33 amino acids (24). M8166Vpr and its duplicated gene product Vpx (3) are known
cells were then infected with the viruses. Virions pro-to be selectively incorporated into viral particles at molar
duced in the supernatants were pelleted by centrifuga-quantities equivalent to those of Gag proteins (4–6). Ge-
tion on a 20% sucrose cushion and layered on a 20–60%netic studies showed that Vpr and Vpx were dispensable
sucrose gradient. The viral particles sedimented sharplyfor replication in human T cell lines (7–9), but important
as monitored by reverse transcriptase (RT) assay as wellfor replication in primary peripheral blood mononuclear
as immunoblot assay for the viral capsid protein p24.cells and macrophages (9–12). Vpr was also shown to
Vpr, which was also detected by immunoblot assay usingfacilitate replication and persistence of simian immuno-
guinea pig anti-HIV-1 Vpr peptide (24), was present onlydeficiency virus in rhesus monkeys (13–15). Expression
in WT virions and in the same peak fractions that con-of Vpr alone was shown to arrest cells in the G2 phase
tained RT and p24 (data not shown). To examine physicalof the cell cycle (16 – 19). Heinzinger et al. (20) reported
interactions of Vpr with other viral components withinthat introduction of mutations in both the matrix protein
the virions, we then carried out coimmunoprecipitation(MA) p17 and Vpr in HIV-1, but not in either of them,
experiments using the purified WT and EN virions. Theattenuated nuclear transportation of the viral preintegra-
virions were lysed by a mild detergent Brij 96 and sub-tion complex in nondividing cells. MA p17 and Vpr, which
jected to immunoprecipitation with guinea pig anti-Vpr,are both nucleophilic proteins (21, 22), may thus consti-
monoclonal anti-p24, monoclonal anti-p17, or guinea pigtute redundant nucleophilic determinants of HIV-1 prein-
anti-HIV-1 not reactive to Vpr. Immunoprecipitates weretegration complex that may promote efficient nuclear
trapped by protein G-Sepharose, subjected to SDS–transportation of viral nucleic acids in nondividing cells
PAGE under nonreducing conditions so that IgG antibod-such as primary macrophages. In the present study, we
ies remained about 150 kDa in size, and electrophoreti-examined physical association of Vpr with other viral
cally blotted to filters. In Fig. 1A, the immunoblot filtercomponents within the virion. Our results suggest that
was probed with guinea pig anti-Vpr. As expectedly, anti-
Vpr (lanes Vpr) precipitated Vpr from the WT virions (lane
WT) but not from the Vpr-negative EN virions (lane EN).1 To whom correspondence and reprint requests should be ad-
dressed. Fax: /81-6-382-2598. Anti-p17 (lanes p17) was also found to coprecipitate Vpr
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from the WT virion (lane WT) but not from the EN virion
(EN). No such coprecipitation of Vpr was seen by anti-
p24 (lanes p24). Vpr was not efficiently coprecipitated by
anti-HIV-1 serum not reactive to Vpr (lanes HIV) probably
because of its low efficiency in precipitation of p17 (see
Fig. 1B, lanes HIV). In Fig. 1B, a similar immunoblot filter
was probed by anti-HIV-1 serum that was not reactive to
Vpr. Anti-p17 (lanes p17) was confirmed to precipitate
p17 but not p24 from both WT and EN virions. Similarly,
anti-p24 (lanes p24) was confirmed to precipitate p24
and several other unknown bands but not p17. On the
other hand, anti-HIV serum (lanes HIV) precipitated both
p24 and p17. Importantly, anti-Vpr (lanes Vpr) was found
to coprecipitate p17 from the WT virion (lane WT) but not
from the Vpr-negative EN virion (lane EN). The bands of
higher molecular sizes in lanes Vpr were nonspecific
because they were also present in the lane EN. In Fig.
1C, we confirmed that anti-Vpr serum but not anti-HIV
serum not reactive to Vpr or monoclonal anti-p17 precipi-
tated Vpr from the extract of Vpr-expressing BHK-21 cells.
Collectively, these results suggest a direct physical asso-
ciation of at least a fraction of Vpr and a fraction of MA
p17 within the mature HIV-1 virion.
To further examine physical interactions between Vpr
and various Gag components, we carried out a protein –
protein interaction assay based on the yeast GAL4 sys-
tem (25). The rational of the assay is that interactions of
two hybrid proteins reconstitute the GAL4 activity and
induce b-galactosidase gene under the control of the
GAL4 site. Vpr and various subregions of Gag were am-
plified by PCR using primers shown in Table 1 and sub-
cloned into either pGBT9 downstream of the GAL4 DNA-
binding domain (DB) or pGAD424 downstream of the
GAL4 activation domain (AC). The results are summa-
rized in Table 2. We did not observe any significant inter-
actions between Vpr and Pr55 or p15 both of which con-
tain p6 (assays 5, 8, 12, and 15). However, negative re-
sults do not exclude interactions between Vpr and Pr55
FIG. 1. Coimmunoprecipitation analysis of Vpr and Gag proteins.
or p15 as nonfusion proteins. On the other hand, theM8166 cells were infected with the wild-type NL432 (WT) or Vpr-nega-
combinations of Vpr and p17 weakly but reproduciblytive NL432 (EN) produced by SW480 transfected with proviral clones
(23). After 5 days postinfection, virions produced in the supernatants induced b-gal activities that were slightly higher than the
were purified by centrifugation on a 20–60% sucrose gradient. Pelleted background levels (assays 6 and 13). Furthermore, the
virions were lysed in a buffer (10 mM Tris–HCl, pH 8.0, 0.15 M NaCl, combinations of Vpr and the C-terminal one-third of p17
2 mM PMSF, 1 mg/ml of pepstatin, 1 mg/ml of leupeptin, 1 mg/ml of
(amino acids 88 to 132) showed significant induction ofchymostatin, and 10 mM iodoacetamide) containing 1% Brij 96. All
b-gal activity (assays 11 and 18). These results demon-reagents were purchased from Sigma (St. Louis, Mo). BHK-21 cells
stably transformed with the Vpr-expressing plasmid pMAMneoR (R) strated a direct association between Vpr and the C-termi-
or the vector pMAMneo alone (N) (24) were treated with 2 mM of nal region of p17.
dexamethazone (Sigma) for 24 hr and lysed in the same lysis buffer.
The viral and cell lysates were briefly centrifuged to remove debris
and precleared for 1 hr at 47 with Protein G-Sepharose (Pharmacia,
Uppsala, Sweden). The lysates were then incubated overnight at 47 were eluted by boiling for 2 min in the electrophoresis sample buffer
with Protein G-Sepharose precoated with the 1st antibody: guinea pig without 2-mercaptoethanol, subjected to 18% SDS–PAGE, and trans-
anti-Vpr raised by immunizing animals with recombinant HIV-1 Vpr ferred to filters (ClearBlot, ATTO, Tokyo). Filters were probed with
expressed by pGEMEX vector (39), monoclonal anti-p24gag (RL4.72.1.1, guinea pig anti-Vpr (24) (A, C) or with guinea pig anti-HIV-1 not reactive
purchased from CosmoBio, Tokyo, Japan), guinea pig anti-HIV-1 raised to Vpr (B). The second reaction was carried out with protein A-horserad-
against purified Vpr-negative HIV-1 virions (Sato et al., unpublished), ish peroxidase and visualized by ECL Western Blotting Detection kit
or monoclonal anti-p17gag (MAB822, purchased from Chemicon Int., (Amersham Japan, Tokyo). The molecular size markers were indicated
CA). After washing extensively with the lysis buffer, immune complexes on the left (kDa).
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TABLE 1
Primers Used for PCR Cloning
Primer Sequence Nucleotide positions
V1 5*-TCGCggatccAGATGGAACAAGCCCCAGAA-3* 5559–5576
V2 5*-TCGCggatccCTAGGATCTACTGGCTCCAT-3* 5849–5830
G1 5*-TATgaattcATGGGTGCGAGAGCGTCG-3* 790–807
G2 5*-GCGgaattcGCAGTTAATCCTGGCCTT-3* 922–939
G3 5*-GCGgaattcGTGCATCAAAGGATAGAT-3* 1051–1068
G4 5*-TCGCgaattcCCTATAGTGCAGAACCT-3* 1185–1202
G5 5*-TCGCgaattcATACAGAAAGGCAATTTT-3* 1921–1938
G6 5*-TCTggatccTGCGAATCGTTCTAGCTC-3* 924–907
G7 5*-TCTggatccCACACAATAGAGGACTGC-3* 1053–1036
G8 5*-GTGgaattcGTAATTTTGGCTGACCTG-3* 1185–1168
G9 5*-ACGgaattcCAAAACTCTTGCTTTAT-3* 1878–1862
G10 5*-ACCgaattcCTTTATTGTGACGAGGG-3* 2294–2283
Note. Subgenomic fragments of pNL432 encoding respective polypeptides were subcloned by using polymerase chain reaction using primers
V1 and V2 for Vpr, G1 and G10 for p55, G1 and G8 for p17, G1 and G6 for p17N(1–45), G2 and G7 for p17M(45–88), G3 and G8 for p17C(88–132),
G4 and G9 for p24, and G5 and G10 for p15. The incorporated BamHI site or EcoRI site is indicated by lower letters. The nucleotide positions are
from pNL432 (23). After PCR, amplified fragments were digested with BamHI or EcoRI and subcloned into the yeast plasmids pGBT9 and pGAD424
(Clontech).
Upon release from infected cells, HIV-1 virions undergo viral protease into the matrix protein p17, the major capsid
protein p24, the nucleocapsid protein p9 and p6, in thea morphological maturation in association with the cleav-
age of the capsid precursor polyprotein Gag Pr55 by the order from the N-terminus. In the mature viral particles, p17
TABLE 2
Interactions of Vpr and Gag Proteins Determined by Two-Hybrid GAL4 Activity in Yeast
Double transformants
Assay GAL4(DB) fusion GAL4(AC) fusion Relative b-gal activity
1 GAL4(DB) GAL4(AC) 1
2 GAL4(DB)-Vpr GAL4(AC)-SV40 1.0 { 0.09
3 GAL4(DB)-p53 GAL4(AC)-Vpr 1.0 { 0.09
4 GAL4(DB)-Vpr GAL4-(AC)-Vpr 1.0 { 0.02
5 GAL4(DB)-Vpr GAL4(AC)-Pr55 1.0 { 0.11
6 GAL4(DB)-Vpr GAL4(AC)-p17 2.3 { 0.04
7 GAL4(DB)-Vpr GAL4(AC)-p24 1.2 { 0.01
8 GAL4(DB)-Vpr GAL4(AC)-p15 1.1 { 0.08
9 GAL4(DB)-Vpr GAL4(AC)-p17N(1–45) 1.0 { 0.14
10 GAL4(DB)-Vpr GAL4(AC)-p17M(45–88) 1.4 { 0.24
11 GAL4(DB)-Vpr GAL4(AC)-p17C(88–132) 18.0 { 2.0*
12 GAL4(DB)-Pr55 GAL4(AC)-Vpr 1.0 { 0.02
13 GAL4(DB)-p17 GAL4(AC)-Vpr 1.6 { 0.07
14 GAL4(DB)-p24 GAL4(AC)-Vpr 1.2 { 0.07
15 GAL4(DB)-p15 GAL4(AC)-Vpr 0.9 { 0.01
16 GAL4(DB)-p17N(1–45) GAL4(AC)-Vpr 1.0 { 0.03
17 GAL4(DB)-p17M(45–88) GAL4(AC)-Vpr 1.0 { 0.03
18 GAL4(DB)-p17C(88–132) GAL4(AC)-Vpr 23.4 { 2.0*
19 GAL4(DB)-p17C(88–132) GAL4(AC)-p17C(88–132) 1.0 { 0.04
20 GAL4(DB)-p17 GAL4(AC)-p17 1.1 { 0.09
21 GAL4(DB)-p17 GAL4(AC)-SV40 1.1 { 0.11
22 GAL4(DB)-p53 GAL4(AC)-p17 1.0 { 0.08
Note. The yeast two-hybrid assay was carried out essentially as described previously (25). The representative results from three separate
experiments are shown. Each assay used three independent clones and mean { SD is shown. Yeast plasmids, pGBT9 carrying GAL4 DNA-binding
domain (GAL4(DB)), pGAD424 carrying GAL4 activation domain (GAL4(AC)), GAL4(AC)-SV40, GAL4(DB)-p53 (the suppressor oncogene product), and
yeast strain HF7c were purchased from Clontech (Palo Alto, CA). The PCR primers used to subclone indicated regions of pNL432 are summarized
in Table 1. *P  0.05 by Fisher’s test.
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